H.C. Wainwright analyst Ed Arce maintained a Buy rating on Akero Therapeutics (NASDAQ:AKRO) Inc on Thursday, setting a price target of $62, which is approximately 77.50% above the present share price of $34.93.
Arce expects Akero Therapeutics Inc to post earnings per share (EPS) of -$0.42 for the third quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Akero Therapeutics, with an average price target of $56.2.
The analysts price targets range from a high of $79 to a low of $41.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$12.38 million. The company's market cap is $1.2 billion.
According to TipRanks.com, H.C. Wainwright analyst Ed Arce is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 13.9% and a 41.10% success rate.
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.